On the other hand, although some markers of disease progression like ABL kinase domain mutations are available, no universal and exclusively specific molecular biomarkers exist to diagnose CML patients during early disease progression [14]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.